Phase 1Completed
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors
- Sponsor
- Merrimack Pharmaceuticals (Industry)
- Enrolment
- 100 planned
- Conditions
- HER-2 Gene Amplification
- Interventions
- Cisplatin, Capecitabine, Trastuzumab and MM-111; Lapatinib +/- Trastuzumab and MM-111; Paclitaxel, Trastuzumab and MM-111; Lapatinib, trastuzumab, paclitaxel, and MM-111; Docetaxel, trastuzumab and MM-111
- Ages
- adults, older adults
- Registry
- NCT01304784
Full record on ClinicalTrials.gov
From the registry
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Primary outcomes
- Determine patient's safety (# of adverse events/serious adverse events) and tolerability of MM-111 in combination with multiple treatment regimens
History
Last registry update
Study completion
Primary completion
Registered
Started